Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05771428
Registration number
NCT05771428
Ethics application status
Date submitted
6/03/2023
Date registered
16/03/2023
Date last updated
10/06/2024
Titles & IDs
Public title
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Query!
Scientific title
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants With Mild Alzheimer's Disease
Query!
Secondary ID [1]
0
0
2022-501918-55-00
Query!
Secondary ID [2]
0
0
M23-515
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Abroad
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease (AD)
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Alzheimer's disease
Query!
Neurological
0
0
0
0
Query!
Dementias
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ABBV-552
Treatment: Drugs - Placebo for ABBV-552
Experimental: ABBV-552 Dose A - Participants will receive ABBV-552 Dose A once daily (QD) for 12 weeks.
Experimental: ABBV-552 Dose B - Participants will receive ABBV-552 Dose B QD for 12 weeks.
Experimental: ABBV-552 Dose C - Participants will receive ABBV-552 Dose C QD for 12 weeks.
Placebo Comparator: Placebo for ABBV-552 - Participants will receive placebo for ABBV-552 QD for 12 weeks.
Treatment: Drugs: ABBV-552
Oral Capsule
Treatment: Drugs: Placebo for ABBV-552
Oral Capsule
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) score
Query!
Assessment method [1]
0
0
The ADAS-Cog was designed to assess the cognitive impairments most common in AD. The ADAS-Cog-14 includes the original 11 items from the ADAS-Cog-11 [1. Spoken language ability, 2. Comprehension of spoken language, 3. Recall of test instructions, 4. Word-findings difficulty in spontaneous speech, 5. Following commands, 6. Naming objects and fingers, 7. Constructional praxis, 8. Ideational praxis, 9. Orientation, 10. Word-recall task, 11. Word-recognition task] and includes 3 additional tasks [12. Number cancellation task, 13. Delayed word recall task, 14. Executive functioning], for increased sensitivity in mild cognitive impairment (MCI) patients. The Total Score of the ADAS-Cog-14 ranges from 0 to 90, with a higher score representing greater impairment.
Query!
Timepoint [1]
0
0
From Baseline (Week 0) through Week 12
Query!
Eligibility
Key inclusion criteria
- Diagnosis of probable Alzheimer's disease according to the National Institute of
Aging-Alzheimer's Association (NIA-AA) (2011) criteria.
- Mini-Mental State Examination (MMSE) score of 20 to 26, a Clinical Dementia Rating
(CDR) global score of 0.5 or 1.0, with a CDR memory score of 0.5 or higher, and at
least 1 CDR functional domain (community affairs, home and hobbies, or personal care)
score of 0.5 or higher at Screening Visit 1.
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
90
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Clinically significant and/or unstable medical conditions or any other reason that the
investigator determines would interfere with participation in this study (e.g., unlikely to
adhere to the study or procedures, keep appointments, or is planning to relocate during the
study) or would make the participant an unsuitable candidate to receive ABBV-552.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/04/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
5/09/2024
Query!
Actual
Query!
Sample size
Target
240
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
St Vincent's Centre for Applied Medical Research /ID# 249843 - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Southern Neurology - Kogarah /ID# 249098 - Kogarah
Query!
Recruitment hospital [3]
0
0
Box Hill Hospital /ID# 249095 - Box Hill
Query!
Recruitment hospital [4]
0
0
Australian Alzheimer's Res Fou /ID# 249097 - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Louisiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Oregon
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Virginia
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Berlin
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Homburg
Query!
Country [18]
0
0
Japan
Query!
State/province [18]
0
0
Hiroshima
Query!
Country [19]
0
0
Japan
Query!
State/province [19]
0
0
Kanagawa
Query!
Country [20]
0
0
Japan
Query!
State/province [20]
0
0
Nara
Query!
Country [21]
0
0
Japan
Query!
State/province [21]
0
0
Niigata
Query!
Country [22]
0
0
Japan
Query!
State/province [22]
0
0
Oita
Query!
Country [23]
0
0
Japan
Query!
State/province [23]
0
0
Saga
Query!
Country [24]
0
0
Japan
Query!
State/province [24]
0
0
Tokyo
Query!
Country [25]
0
0
New Zealand
Query!
State/province [25]
0
0
Christchurch Central
Query!
Country [26]
0
0
Spain
Query!
State/province [26]
0
0
Barcelona
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Cantabria
Query!
Country [28]
0
0
Spain
Query!
State/province [28]
0
0
Navarra
Query!
Country [29]
0
0
Spain
Query!
State/province [29]
0
0
Madrid
Query!
Country [30]
0
0
Spain
Query!
State/province [30]
0
0
Salamanca
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
Bristol, City Of
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
Birmingham
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
London
Query!
Country [34]
0
0
United Kingdom
Query!
State/province [34]
0
0
Motherwell
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most
common cause of dementia in the elderly population. Clinical symptoms of the disease may
begin with occasional forgetfulness such as misplacement of items, forgetting important dates
or events, and may progress to noticeable memory loss, increased confusion and agitation, and
eventually, loss of independence and non-responsiveness. This study will assess how safe and
effective ABBV-552 is in treating symptoms of early AD. Adverse events, change in disease
activity, how ABBV-552 moves through body of participants and the body response to ABBV-552
will be assessed.
ABBV-552 is an investigational drug being developed for the treatment of Alzheimer's disease
(AD). Study doctors put the participants in 1 of 4 groups (3 active dose groups and a placebo
group), called treatment arms. Each group receives a different treatment. There is a 1 in 4
chance that participants will be assigned to placebo. Approximately 240 participants aged
50-90 years with mild AD will be enrolled in approximately 60 sites across the world.
Participants will receive oral ABBV-552 or placebo capsules once daily for 12 weeks and
followed for 30 days after the last dose of study drug.
There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at a hospital or
clinic. The effect of the treatment will be checked by medical assessments, blood tests,
checking for side effects and completing questionnaires.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05771428
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ABBVIE INC.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05771428
Download to PDF